Laguna Lab
Investigating How Infection and Inflammation Drive Airway Destruction in Children With Cystic Fibrosis
Despite recent therapeutic advances in the care of people with cystic fibrosis (CF), infection and inflammation in the lower airways remains a significant cause of increased morbidity and early mortality. Chloride channel dysfunction leads to thick, stagnant mucus, infection and inflammation in the lungs, which results in obstructive lung disease and progressive damage to lung tissue. How and why this is remains an area of intense research focus.
Dr. Laguna’s laboratory is focused on studying infections in the CF airway, using next-generation sequencing techniques to identify bacterial and fungal communities that inhabit the lower airways. Using oropharyngeal swabs, sputum and bronchoalveolar lavage fluid samples from people with and without CF, Laguna aims to better define what pathogens live in the lower airways.
Through collaborations with investigators nationwide, the Laguna Laboratory aims to identify new therapeutic approaches to infection and inflammation in the lungs of people with CF to improve quality of life and extend life expectancy. Additionally, the Laguna Laboratory aims to develop a large biobank of airway specimens to inform additional investigation into other lung diseases such as primary ciliary dyskinesia.
Theresa Annette Laguna, MD, MSc
Dr. Laguna has developed an investigator-initiated, independently funded research laboratory focused on studying infection and inflammation in the lower airways of people with cystic fibrosis (CF). She is a pediatric pulmonologist with a clinical and research interest in CF as well as primary ciliary dyskinesia and health disparities.
-
Matt Fought, BS, MS
Research Scientist II
With experience in microbiological testing in industry, I’m excited to join Dr. Laguna’s laboratory, transition into research and understand the role that microorganisms play in cystic fibrosis. I’m thrilled to join a dynamic and diverse team that’s committed to understanding this complex condition and contributing to transformative advances in healthcare.
-
Ali Quinn, BA
Clinical Research Coordinator I
It's an honor to be part of Dr. Laguna's laboratory team as her CRC. Having prior experience conducting clinical trials, Dr. Laguna's protocols have offered me a unique look into investigator-led studies. Our team is committed to a patient-centered and inclusive approach in examining the complex questions of cystic fibrosis.